Latest Insider moments: Stergiou Angelos M., SELLAS Life Sciences Group Inc. [SLS] President and CEO sold 6,494 shares


SELLAS Life Sciences Group Inc.’s recent filing unveils that its President and CEO Stergiou Angelos M. unloaded Company’s shares for reported $16938.0 on Dec 05. In the deal valued at $2.61 per share,6,494 shares were sold. As a result of this transaction, Stergiou Angelos M. now holds 161,689 shares worth roughly $ 0.28 million.

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".


Then, WOOD BARBARA A sold 2,153 shares, generating $5,576 in total proceeds. Upon selling the shares at $2.59, the EVP, Gen. Counsel, Corp. Sec. now owns 56,344 shares.

Before that, Burns John Thomas sold 1,159 shares. SELLAS Life Sciences Group Inc. shares valued at $3,002 were divested by the Senior VP, Finance & CAO at a price of $2.59 per share. As a result of the transaction, Burns John Thomas now holds 29,347 shares, worth roughly $50770.31.

Cantor Fitzgerald initiated its SELLAS Life Sciences Group Inc. [SLS] rating to an Overweight in a research note published on Monday, July 21, 2021; the price target was $18. PT values the company’s stock at a premium of 90.39 to its Monday closing price. A number of analysts have revised their coverage, including Oppenheimer’s analysts, who began to cover the stock in early November with a ‘”an Outperform”‘ rating. H.C. Wainwright began covering SLS with “Buy” recommendation on April 02, 2018. Maxim Group revised its rating on March 19, 2018. It rated SLS as “a Buy” which previously was an “a Hold”.

Price Performance Review of SLS

On Monday, SELLAS Life Sciences Group Inc. [NASDAQ:SLS] saw its stock jump 1.17% to $1.73. On the same session, the stock had its day’s lowest price of $1.70, but rose to a high of $1.83. Over the last five days, the stock has lost -52.21%. SELLAS Life Sciences Group Inc. shares have fallen nearly -26.69% since the year began. Nevertheless, the stocks have fallen -70.68% over the past one year. While a 52-week high of $7.40 was reached on 02/06/23, a 52-week low of $1.59 was recorded on 02/24/23. SMA at 50 days reached $2.9403, while 200 days put it at $2.8425. A total of 1.57 million shares were traded, compared to the trading of 6.91 million shares in the previous session.

Levels Of Support And Resistance For SLS Stock

The 24-hour chart illustrates a support level at 1.6767, which if violated will result in even more drops to 1.6233. On the upside, there is a resistance level at 1.8067. A further resistance level may holdings at 1.8833. The Relative Strength Index (RSI) on the 14-day chart is 27.92, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.8437, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 94.14%. Stochastics %K at 23.88% indicates the stock is a holding.

How much short interest is there in SELLAS Life Sciences Group Inc.?

A steep rise in short interest was recorded in SELLAS Life Sciences Group Inc. stocks on Jan 12, 2023, dropping by 30000.0 shares to a total of 1.2 million shares. Yahoo Finance data shows the prior-month short interest on Dec 14, 2022 was 1.23 million shares. There was a decline of -2.5%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 5.85% of the overall stock float, the days-to-cover ratio (short ratio) fell to 10.24.

SELLAS Life Sciences Group Inc. [SLS] – Who Are The Largest Shareholders?

In filings from The Vanguard Group, Inc., it is revealed that the company now owns 849,741 shares, or roughly 4.13% of the outstanding SLS shares. In other words, the investor’s shares have risen by 25,965 from its previous 13-F filing of 823776.0. Additionally, Empery Asset Management LP decreased -66.76% of its stake after which the total value it holdings stand at $1,024,107, while BlackRock Fund Advisors added 0.81% of its stake to hold $0.85 million in the firm. Over the last quarter, Geode Capital Management LLC purchased 43,347 shares of SELLAS Life Sciences Group Inc., while Equitable Advisors LLC bought 3,000 shares. At present, SSgA Funds Management, Inc. is holding 71,729 shares valued at $0.24 million. Millennium Management LLC owned 61,179 shares of the company at the time of its most recent 13F filing, worth $0.2 million.

According to FactSet, SELLAS Life Sciences Group Inc.’s share price will average $8.25 in the next year, based on opinions of analysts polled by the firm. This is up nearly 397.08 percent from its previous closing price of $1.71. Analysts expect SELLAS Life Sciences Group Inc. stock to reach the higher price of $12.00, while the lowest price estimate is $4.00. However, 4 analysts have rated SLS stock as a Buy in their predictions for 2023.


Please enter your comment!
Please enter your name here